Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 66 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Unraveling the Immune Mechanisms and Therapeutic Targets in Lung Adenosquamous Transformation
Haiyan Xu,Ying Yang,PingLi Wang, Shengnan Lin, Xiaochun Zhang, Huiwen Ni, Zhiyong Xu
Frontiers in Immunology (2025)
Cited0Views0Bibtex
0
0
Characteristics of Mast Cell Infiltration in Lung Adenocarcinoma and Its Impact on Prognosis
Zijian Qiu,Guanchao Pang, Xia Xu, Jun Lin,Pingli Wang
Discover Oncologyno. 1 (2024)
Cited0Views0WOSBibtex
0
0
Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC
T. Wang,P. -L. Wang,Y. -X. Song,H. Chen, L. Li, Y. Wang,L. -R. Ding, X. -J. Huang,B. Zheng, J. -R. Zhang, J. -W. Liu, D. -X. Zhu,L. Tian, L. -L. Jiang,P. Zhou, M. -G. Su,D. Pu, R. Jiang, K. -L. Huang,Y. -S. Wang, C. Chen, Q. -H. Zhou
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S570-S571
Cited0Views0Bibtex
0
0
P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
Q. Zhou, Y. Pan, X. -N. Yang,Q. -T. Yu, W. -H. Zhao, T. -M. Zhang, A. -W. Liu,W. -N. Feng,X. -R. Dong, Y. Yang,M. -F. Zhao,P. -L. Wang,Y. Fan, H. Luo, B. -H. Wang,Y. -S. Shu, Y. Liu, J. Zhao,Q. Bu, J. Li, F. Xu, L. -H. Sun,S. -Y. M. Liu,Y. -L. Wu
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S338-S338
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 66

#Citation: 1078

H-Index: 18

G-Index: 32

Sociability: 6

Diversity: 3

Activity: 27

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn